Related Experiment Video

Updated: Jun 13, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Pharmacological therapy of cardiorenal syndromes and heart failure

Andrew A House1

  • 1Division of Nephrology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ont., Canada.

Contributions to Nephrology
|April 30, 2010
PubMed

Insights

Cardiorenal syndromes (CRS) involve heart and kidney dysfunction. Understanding drug effects on both organs is crucial for managing CRS and heart failure, impacting renal and cardiac outcomes.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Cardiorenal syndromes (CRS) represent a complex interplay between heart and kidney dysfunction.
  • Dysfunction in one organ system can precipitate or exacerbate issues in the other, creating a challenging clinical scenario.

Purpose of the Study:

  • To review pharmacological therapies for acute and chronic cardiorenal syndromes.
  • To discuss novel treatment strategies for preventing or managing worsening renal function in acute decompensated heart failure.
  • To highlight the necessity for rigorous future research in cardiorenal medicine.

Main Methods:

  • Review of existing literature on pharmacological interventions in CRS.
  • Discussion of current and emerging drug regimens.
  • Analysis of the impact of cardiovascular and renal treatments on the contralateral organ.

Main Results:

  • Pharmacological treatments for cardiovascular diseases can beneficially or detrimentally affect kidney function.
  • Renal disease management strategies may impact cardiac performance and cardiovascular risk.
  • Current understanding emphasizes the bidirectional influence of treatments on heart and kidney health.

Conclusions:

  • Effective management of CRS necessitates a comprehensive understanding of drug effects on both the heart and kidneys.
  • Tailoring pharmacological approaches is essential to optimize outcomes and minimize adverse events in patients with CRS.
  • Further high-quality studies are imperative to advance the treatment paradigms for cardiorenal syndromes.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...